Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches
- 1 June 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 29 (3) , 231-236
Abstract
Until now, malignancy has been considered a cellular problem represented by the perturbed (uncontrolled) division of the cells associated with invasion and metastasis. Contrary to this classical approach, a new perspective suggests that cancerous disease is, in fact, a supracellular problem represented by inadequate evolution of complex supracellular processes (embryogenesis, development, regeneration, etc.). Such complex processes would be disconnected from the real needs of the body, inducing unnecessary or even dangerous events such as an exacerbated rate of the cell division, angiogenesis, immunosuppression (specific to embryogenesis and melanoma), invasion (mediated by trophoblastic/placental factors in melanoma), and migration (specific to neural crest cells, which generate melanocytes – the most common origin for melanoma). As a result, a correct and comprehensive interpretation of cancer (causes, evolution, therapy, and prevention) should be conducted from a supracellular perspective. After presenting the supracellular perspective, this article further investigates the favorable evolution of malignant melanoma in two distinct situations: in patients receiving no therapy and in patients treated with immune-checkpoint inhibitors. In patients receiving no therapy, spontaneous regressions of melanoma could be the result of several autoimmune reactions (inducing not only melanoma regression but also vitiligo, an autoimmune event frequently associated with melanoma). Patients treated with immune-checkpoint inhibitors develop similar autoimmune reactions, which are clearly correlated with better therapeutic results. The best example is vitiligo, which is considered a positive prognostic factor for patients receiving immune-checkpoint inhibitors. This finding indicates that immune-checkpoint inhibitors induce distinct types of autoimmune events, some corresponding to specific favorable autoimmune mechanisms (favoring tumor regression) and others to common unfavorable adverse reactions (which should be avoided or minimized). In conclusion, the spectrum of autoimmune reactions induced by immune-checkpoint inhibitors should be restricted in the near future to only these specific favorable autoimmune mechanisms. In this way, the unnecessary autoimmune reactions/autoaggressions could be avoided (a better quality of life), and treatment specificity and efficiency should increase (a higher response rate for melanoma therapy).Keywords
This publication has 70 references indexed in Scilit:
- A word of caution: do not wake sleeping dogs; micrometastases of melanoma suddenly grew after progesterone treatmentBMC Cancer, 2013
- Corticotropin-releasing hormone exerts direct effects on neuronal progenitor cells: implications for neuroprotectionMolecular Psychiatry, 2013
- Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partnersBritish Journal of Dermatology, 2012
- The face in congenital melanocytic nevus syndromeAmerican Journal of Medical Genetics Part A, 2012
- Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohortJournal of the European Academy of Dermatology and Venereology, 2011
- Spontaneous regression of transplacental metastases from maternal melanoma in a newborn: case report and review of the literatureMelanoma Research, 2010
- Can cancer be reversed by engineering the tumor microenvironment?Seminars in Cancer Biology, 2008
- Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressivenessNature Medicine, 2006
- Human embryonic genes re-expressed in cancer cellsOncogene, 2001
- Scale of body pattern adjusts to available cell number in amphibian embryosNature, 1981